Genmab — September 2014
-
Det er nogle gode Dara slides i appendix. præklinisk model med Dara-CHOP og Dara-R-CHOP i DLBCL er imponerende. Ligeledes Dara Vincristin i ALL.
-
ja ligner det ikke 100% ORR i Dara + Vincristine ?
-
På Ofa+Ibrutinib slide står Dosing Sequence optimization required. Det kan være derfor det trækker ud med fase 3
-
Det er i en præklinisk model. Men effekten er ikke til at tage fejl af
-
Syntes mere og mere tegner lyst for Daratumumab
-
kan vi også få gode data fra phase I studier idenfor MM i ALL, AML, DLBLC etc. så kan det stof jo gå amok i salg
-
jep
-
Novod skriver i den seneste analyse: We maintain our Strong Buy rating on Genmab and raise our target
p
rice to DKK 350 (315), with a blue-sky scenario above DKK 500 per
share. We believe that Genmab/J&J's Daratumumab (Dara) will set a
new standard in the treatment of multiple myeloma and help drive the
MM antibody market to USD 7-9bn in ten to 15 years. We believe that
Dara will be first- and best-in-class, likely two to three years ahead ofthe competition. We consequently now model Dara to ca
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind